Objective From the perspective of a China health insurance system, through geting an economic evaluation of Trastuzumab in the Adjuvant Treatment for early HER2-positive breast cancer, to promote breast cancer specification and provide the reference for diagnosis and treatment and health care policies.Methods A Markov health-state transition model was constructed to simulate the natural development of breast cancer based on HERceptin Adjuvant (HERA) trial, estimate costs and disease progression over a lifetime perspective with annual transition cycles, and evaluate the cost-effectiveness of 1-year adjuvant trastuzumab treatment group compared with the standard adjuvant chemotherapy. Results If adopted Trastuzumab by an adjuvant treatment, the expectations of patients survival, quality adjusted life years up to 4.30 years and 2.86 years respectively, extended by a year needed to increase medical costs 96334 yuan, 144936 yuan respectively. Conclusion In hubei province, the results suggest that the 1-year adjuvant trastuzumabtreatment is cost-effective. Hubei or other other provinces and cities that have higher or equal economy development level can consider let trastuzumab into the medical insurance directory.